Barr gets FDA OK for generic Yasmin contraceptive
NEW YORK (Reuters) - Barr Pharmaceuticals Inc (BRL.N: Quote, Profile, Research) said on Friday the U.S. Food and Drug Administration has approved the sale of its generic version of the oral contraceptive Yasmin.
Barr challenged the Yasmin patent held by Bayer AG (BAYG.DE: Quote, Profile, Research), and in March, a U.S. district court found that the patent held by Bayer was invalid because it was obvious. The German drugmaker has appealed the ruling.
Yasmin, known generically as drospirenone and ethinyl estradiol, had branded annual sales of about $575 million, Barr said.
The generic drugmaker said it planned to start selling its version of Yasmin in mid 2008. It expects, as the first to file for approval, to have 180 days of exclusivity before any other generic companies can start selling the contraceptive.
Barr shares closed up $1.89 at $39.99 on the New York Stock Exchange.
(Reporting by Bill Berkrot, Editing by Toni Reinhold)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Consulting Opportunity; Healthcare Expertise Required
Details: ...topic area experts for paid consultations. We are seeking Healthcare professionals with advanced knowledge and insights from diverse...
Clinical Research Solutions and Healthcare Compliance Associate
Details: ...leading academic institutions, healthcare organizations, and the law...Clinical Research Solutions/Healthcare Compliance team is a national...
CEO - Chief Executive Officer - Healthcare - Hospital
Details: ...has worked in the healthcare industry either...level, within the healthcare vertical. Utilizing...for hospitals and healthcare systems totaling...
Healthcare Sales Representative
Details: ...commercial business, healthcare, and government...salesperson to cover the healthcare and business sector...consideration in targeted healthcare building and renovation...
Sphere
Uneasy Truce
Myanmar faces mass deaths
